Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InnoCan PharmaFRA:IP40 +4.51%62 Equity-to-Asset is 0.48 as of Mar. 2026, which is 11% below its 10-year median of 0.54. GuruFocus rates FRA:IP40 with a GF Score™ of 62/100 and a GF Value™ of €9.51 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 1,993 Consumer Packaged Goods companies, InnoCan Pharma ranks worse than 59.56% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. InnoCan Pharma's Total Stockholders Equity for the quarter that ended in Mar. 2026 was €4.50 Mil. InnoCan Pharma's Total Assets for the quarter that ended in Mar. 2026 was €9.38 Mil.
Therefore, InnoCan Pharma's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.48.
The historical rank and industry rank for InnoCan Pharma's Equity-to-Asset or its related term are showing as below:
FRA:IP40'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.83 Med: 0.54 Max: 0.92
Current: 0.48
During the past 8 years, the highest Equity to Asset Ratio of InnoCan Pharma was 0.92. The lowest was -0.83. And the median was 0.54.
FRA:IP40's Equity-to-Asset is ranked worse than 59.56% of 1993
companies
in the Consumer Packaged Goods industry
Industry Median: 0.55
vs FRA:IP40: 0.48
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
InnoCan Pharma Equity-to-Asset Related Terms
InnoCan Pharma Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for InnoCan Pharma's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:IP40 vs PG, CL, KVUE: Equity-to-Asset Comparison
For the Household & Personal Products subindustry, InnoCan Pharma's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InnoCan Pharma Equity-to-Asset vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, InnoCan Pharma's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where InnoCan Pharma's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
InnoCan Pharma's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InnoCan Pharma (FRA:IP40) has a Equity-to-Asset of 0.48 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on InnoCan Pharma and its competitors. This is 11% below median its historical median of 0.54. According to the industry distribution chart, InnoCan Pharma ranks #1187 out of 1993 companies in the Consumer Packaged Goods industry, placing it in the top 59.6%.
Is InnoCan Pharma's Equity-to-Asset too high?
InnoCan Pharma's current Equity-to-Asset of 0.48 is 11% below median its 10-year median of 0.54. The Consumer Packaged Goods industry median Equity-to-Asset is 0.55. InnoCan Pharma's value of 0.48 is 12.7% below this industry median. Based on the distribution chart, InnoCan Pharma ranks #1187 out of 1993 companies in the Consumer Packaged Goods industry, which is below the industry midpoint. Overall, InnoCan Pharma has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InnoCan Pharma's Equity-to-Asset compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, InnoCan Pharma ranks #1187 out of 1993 companies for Equity-to-Asset. This places InnoCan Pharma in the lower half of its industry. The industry median Equity-to-Asset is 0.55. InnoCan Pharma's value of 0.48 is 12.7% below this benchmark. While the company's 10-year median is 0.54 vs. the industry median of 0.55, InnoCan Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Consumer Packaged Goods company?
The median Equity-to-Asset among Consumer Packaged Goods companies is 0.55, based on 1,993 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. InnoCan Pharma's current Equity-to-Asset of 0.48 is 12.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on InnoCan Pharma and its competitors. For the Consumer Packaged Goods industry, the median Equity-to-Asset is 0.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InnoCan Pharma's current Equity-to-Asset is 0.48, which is 11% below median its own 10-year median of 0.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCan Pharma stock overvalued right now?
Based on GuruFocus' analysis, InnoCan Pharma (FRA:IP40) is currently considered Possible Value Trap. The stock's GF Value™ is €9.51, compared to a current price of €1.51 — trading 84.2% below its estimated fair value. The current Equity-to-Asset is 0.48, which is 11% below median its 10-year median of 0.54 and 12.7% below the Consumer Packaged Goods industry median of 0.55. InnoCan Pharma's overall GF Score™ is 62/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For InnoCan Pharma (FRA:IP40), the current Equity-to-Asset is 0.48 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InnoCan Pharma (FRA:IP40) Overvalued in 2026?
Based on GuruFocus' analysis, InnoCan Pharma stock appears to be undervalued.
The current stock price of €1.51 is trading 84.2% below its estimated GF Value™ of €9.51.
GuruFocus considers InnoCan Pharma to be Possible Value Trap.
Key valuation signals for FRA:IP40:
Equity-to-Asset: 0.48 (11% below median its 10-year median of 0.54)
GF Value™: €9.51 vs. price of €1.51 (84.2% below fair value)
Industry Position: 12.7% below the Consumer Packaged Goods median (#1187 of 1993)
No single metric tells the full story. See the FRA:IP40 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InnoCan Pharma Corp develops consumer wellness and pharmaceutical products. It has developed a preclinical-stage Cannabidiol-loaded Liposome injection Platform (CBD-LPT) for non-opioid pain management, and is involved in developing and marketing various self-care and CBD beauty products. Additionally, the Group offers cosmetic products such as anti-aging beauty sleeping masks, anti-puffiness eye serum, anti-aging facial serum, hair cream, etc., which are sold mainly through online marketplaces. Its operating segments are: Online sales and Other operations. The majority of its revenue is generated from the Online sales segment, which engages in the development, manufacture, and marketing of cosmetic products. Geographically, the Group generates maximum revenue from the United States.
62GF Score
Get the complete analysis for FRA:IP40
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:IP40 has been successfully added to your 
